ERBB2 and breast carcinoma: As targeted therapy can be implemented for HER2-positive breast cancer, we analyzed the correlation of VDAC1 protein expression with the prognosis of HER2-positive breast cancer patients and HER2-negative breast cancer patients, respectively.